Mylan launches Avelox generic in USA

Mylan has launched a generic version of Bayer’s (BAYN: DE) Avelox (moxifloxacin) in the USA.

The drugmaker claims it is the first AP-rated generic version of the drug, which is indicated for treating infections in adults caused by designated susceptible bacteria in community acquired pneumonia, skin and skin structure infections, complicated intra-abdominal infections, plague, acute bacterial sinusitis and acute bacterial exacerbation of chronic bronchitis.